The increasing complexity of immuno-oncology clinical trials heightens the importance of devising a sound strategy for evaluating disease biomarkers as potential trial endpoints or as determinants of eligibility criteria. That places a premium on comprehensive strategic planning to enable biospecimen collection and evaluation as a crucial step in biomarker exploration, particularly with regard to developing potential companion diagnostic (CDx) strategies.

On February 18, 2021, Rob Fannon, General Manager for Biospecimen Solutions at Precision for Medicine, delivered a presentation entitled, Biospecimens and Biomarkers for Your CDx Strategy at the 28th International Molecular Med Tri-Con Virtual Conference & Expo, a leading international forum for the precision medicine community. Precision for Medicine, a global leader in supplying biospecimens, lab services, and CRO services to the life sciences industries, was pleased to have Fannon share his strategic insights with the Tri-Con audience.

Corralling the Movement of Tissue Samples in Immuno-oncology Trials

In a 2016 survey conducted as part of an Applied Clinical Trials webinar, participants rated "highly complex studies" as the most challenging aspect of immuno-oncology clinical trials. A key driver of that complexity is the movement of tissue samples throughout the trial laboratory ecosystem.